Regulated cell death (RCD), also well-known as programmed cell death (PCD), refers to the
form of cell death that can be regulated by a variety of biomacromolecules, which is …

Cancer is the second leading cause of death in the US. Current major treatments for cancer
management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy …

Molecular target inhibitors have been regularly approved by Food and Drug Administration
(FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and …

In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …

Combinations of BRAF inhibitors and MEK inhibitors (BRAFi+ MEKi) are FDA-approved to
treat BRAF V600E/K-mutant melanoma. Efficacy of BRAFi+ MEKi associates with cancer cell …

Metastatic melanoma is challenging to manage. Although targeted-and immune therapies
have extended survival, most patients experience therapy resistance. The adaptability of …

Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a
mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy …

The mitogen-activated protein kinases (MAPK) pathway, often known as the RAS-RAF-MEK-
ERK signal cascade, functions to transmit upstream signals to its downstream effectors to …

The discovery that a subset of human tumours is dependent on mutationally deregulated
BRAF kinase intensified the development of RAF inhibitors to be used as potential …

Melanoma is an aggressive malignancy originating from pigment-producing melanocytes.
The development of targeted therapies (MAPK pathway inhibitors) and immunotherapies …